Update for Josh: A Change in Treatment is only a Little Unsettling
2021 Treatment update
patient
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
Original Publication Date
Article Source
External Web Content
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and…
Pack your Bags and Head to the Hospital - Hailey's Story
“You will need to pack your bags and head to Children’s Hospital, we think it’s leukemia.”
Only a few days after a Complete Blood Count, Christy, Hailey's mom, heard these words from Hailey’s doctor. Hailey had just started kindergarten.
At summer dance camp, Hailey won the award for “Most Tired.” That puzzled her mom. As kindergarten progressed, Christy noticed the fatigue. She assumed that kindergarten must be exhausting for children. Christmas was approaching when she noticed Hailey’s bruises, in odd places on her body.
Life Interrupted – Nick’s Fight Against Aplastic Anemia
Here is Nick's story, as told by his mom, Pamela Karavite
Hereditary MDS
Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Lucy Godley, MD, PhD
Lucy Godley, MD, PhD, (UChicago Medicine) discusses the connection between heredity and MDS. While MDS is most often not inherited, there are some genetic mutations and other genetic conditions that can lead to a diagnosis of MDS.
Ivana Gojo, MD
Institution
Johns Hopkins Sidney Kimmel Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
About
Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Original Publication Date
Article Source
External Web Content
Key Points In patients with RR-AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months. NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS. Abstract…
Scientists discover two unique subtypes of a prominent mutation in patients with AML
Original Publication Date
Article Source
External Web Content
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear…
Jane Liesveld, MD
Institution
Strong Memorial Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Robert Hasserjian, MD
Institution
Massachusetts General Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.